Form 4: Curis Inc. Director Anne Elizabeth Borgman Reports Stock Option Grant

Director Anne Elizabeth Borgman reports the acquisition of stock options in Curis Inc. following shareholder approval of the company's Fifth Amended and Restated 2010 Stock Incentive Plan.

Summary

• Anne Elizabeth Borgman, a director of Curis Inc., reported a transaction involving derivative securities.
• On May 21, 2024, Borgman acquired 4,250 non-qualified stock options with an exercise price of $11.62.
• The options were granted on January 20, 2024, contingent upon shareholder approval of Curis's Fifth Amended and Restated 2010 Stock Incentive Plan, which was obtained on May 21, 2024.
• The options vest as to 100% of the underlying shares on January 20, 2025.
• Following the reported transaction, Borgman directly owns 4,250 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The filing indicates standard executive compensation practices and shareholder approval of the incentive plan, which are generally viewed favorably.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• Shareholder approval of the Fifth Amended and Restated 2010 Stock Incentive Plan indicates support for the company's compensation strategy.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting date of the options.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders by incentivizing them to increase the company's stock value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their director compensation plans.
• The vesting schedule of the options (100% on January 20, 2025) is a fairly standard vesting period for such grants.

Stakeholder Impact

• Shareholders may view the option grant as a positive incentive for the director to work towards increasing shareholder value.
• Employees may see the shareholder approval of the stock incentive plan as a positive sign of the company's commitment to employee compensation.

Key Dates